- Report
- September 2025
- 26 Pages
Norway
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 19 Pages
Bulgaria
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 25 Pages
Japan
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 23 Pages
Norway
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Czech Republic
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 25 Pages
Belgium
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 21 Pages
Bulgaria
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 24 Pages
Czech Republic
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 30 Pages
United States
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 27 Pages
Belgium
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 28 Pages
Japan
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 25 Pages
Norway
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 24 Pages
China
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 27 Pages
Germany
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 26 Pages
United Kingdom
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 25 Pages
Chile
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 25 Pages
Colombia
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 27 Pages
Mexico
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 27 Pages
South Korea
From €995EUR$1,181USD£890GBP
- Report
- September 2025
- 25 Pages
Cameroon
From €995EUR$1,181USD£890GBP

The Drugs by Therapeutic Area market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs for specific medical conditions. These drugs are designed to treat a wide range of diseases, from cancer to mental health disorders. Companies in this market typically specialize in one or more therapeutic areas, such as oncology, neurology, or cardiology. They develop drugs that target specific medical conditions and then market them to healthcare providers and patients. Companies in this market include Pfizer, Merck, Novartis, GlaxoSmithKline, and Sanofi. Show Less Read more